Epirubicin

Across CCLE and GDSC cell-line panels, response to Epirubicin is significantly associated with the mutation status of multiple genes, with STOMACH cell lines showing a particularly strong set of associations.

The most reproducible Epirubicin response-associated genes across cancer lineages are MUC5B, MYO18B, and RIMS2, each associated with drug response in up to 4 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, Epirubicin response grouped by MUC5B status in STOMACH.

Mutation status biomarkers of Epirubicin response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
STOMACH	MUC5B →	+2.491	+0.536	.049	.032	3	4
LUNG_SCLC	MYO18B →	-2.000	-0.389	.041	.040	3	3
LUNG_SCLC	RIMS2 →	-3.321	-0.559	.002	.004	3	3
LARGE_INTESTINE	RALGAPA2 →	+2.710	+0.566	.027	.012	3	3
BREAST	EPPK1 →	-2.807	-0.497	.030	.015	3	3
SOFT_TISSUE	TP53 →	-1.862	-0.649	.029	.013	3	3

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Epirubicin response by MUC5B status — STOMACH

Explore this box plot interactively →